Titan Pharmaceuticals, Inc. (OTCBB:TTNP) haben angekündigt, dass die New Drug Application (NDA) für Probuphine ® zur Überprüfung akzeptiert und Priorität Bezeichnung von der US Food and Drug Administration (FDA) erteilt wurde...
People round the world square measure involved with providing healthy living conditions, medications, preventive care and additional for his or her voters in order that they will live long, healthy lives. These world health care blogs mirror the considerations from individuals of all countries and walks of life and might assist you study health care problems that have an effect on individuals young and previous. Check these bent study technology, drugs, food safety and far additional.
Tuesday, January 22, 2013
Probuphine ® erhält FDA Priority Review Bezeichnung für Erwachsene Patienten mit Opioidabhängigkeit
Labels:
Bezeichnung,
erhlt,
Erwachsene,
Opioidabhngigkeit,
Patienten,
Priority,
Probuphine,
Review
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment